MOUNTAIN VIEW, CA – HeartFlow, Inc. (Nasdaq: HTFL), a medical technology company pioneering AI in the diagnosis of heart disease, has successfully completed its initial public offering (IPO), raising approximately $364.2 million in gross proceeds, the company announced.
The company’s common stock began trading on the Nasdaq Global Select Market on August 8 under the ticker symbol “HTFL.”
In the offering, HeartFlow sold 19,166,667 shares at a price of $19.00 per share. The total includes the full exercise of the underwriters’ option to purchase an additional 2,500,000 shares, a move that typically signals strong investor demand. All shares were sold directly by HeartFlow.
HeartFlow is focused on revolutionizing the diagnosis and management of coronary artery disease. The company’s non-invasive technology platform utilizes artificial intelligence to create personalized 3D models of a patient’s coronary arteries, helping clinicians make more informed treatment decisions. According to the company, its technology has already been used in the clinical management of over 400,000 patients globally.
The IPO was managed by a syndicate of leading financial institutions. J.P. Morgan, Morgan Stanley, and Piper Sandler served as the joint book-running managers, with Stifel and Canaccord Genuity acting as co-managers for the offering.
The public offering proceeded after the company’s registration statement was declared effective by the U.S. Securities and Exchange Commission (SEC), confirming compliance with federal regulations.
